A “significant milestone” has been reached with the HSE’s approval of a novel treatment option that might lower the risk of recurrence of breast cancer by 30% in patients at high risk of the disease, reports RTE.
The pharmaceutical business Eli Lilly produces the medication, abemaciclib, which is prescribed to patients with high-risk oestrogen-driven breast cancer.
Oncologists state that oestrogen-driven breast cancer accounts for around 70% of all cases and that a significant risk of recurrence exists in about 25% of these instances, reports RTE.
The medication will be supplied as a pill to qualified individuals for a period of two years.
It will be accessible as of June 1st, reports RTE.
Tell us your thoughts in the Facebook post and share this with your friends.
